150 related articles for article (PubMed ID: 7799078)
1. Phosphorus-32-chromic phosphate for ovarian cancer: I. Fractionated low-dose intraperitoneal treatments in conjunction with platinum analog chemotherapy.
Pattillo RA; Collier BD; Abdel-Dayem H; Ozker K; Wilson C; Ruckert AC; Hamilton K
J Nucl Med; 1995 Jan; 36(1):29-36. PubMed ID: 7799078
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study.
Young RC; Brady MF; Nieberg RK; Long HJ; Mayer AR; Lentz SS; Hurteau J; Alberts DS
J Clin Oncol; 2003 Dec; 21(23):4350-5. PubMed ID: 14645424
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group.
Varia MA; Stehman FB; Bundy BN; Benda JA; Clarke-Pearson DL; Alvarez RD; Long HJ;
J Clin Oncol; 2003 Aug; 21(15):2849-55. PubMed ID: 12885800
[TBL] [Abstract][Full Text] [Related]
4. Update on the role of radiotherapy in ovarian cancer.
Lanciano R; Reddy S; Corn B; Randall M
Semin Oncol; 1998 Jun; 25(3):361-71. PubMed ID: 9633849
[No Abstract] [Full Text] [Related]
5. Pleuroperitoneal migration of intraperitoneal phosphorus-32-chromic phosphate therapy for stage I ovarian carcinoma.
Wilkinson RH
J Nucl Med; 1996 Apr; 37(4):636-9. PubMed ID: 8691256
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal radioactive chromic phosphate (P32) in the treatment of ovarian cancer.
Powell JL; Kirchner AB
J Med Assoc Ga; 1984 Jan; 73(1):21-5. PubMed ID: 6707541
[No Abstract] [Full Text] [Related]
7. Intraperitoneal radioactive chromic phosphate P 32 in the treatment of ovarian cancer.
Powell JL; Burrell MO; Kirchner AB
South Med J; 1987 Dec; 80(12):1513-7. PubMed ID: 3423895
[TBL] [Abstract][Full Text] [Related]
8. Five and ten year estimated survival and disease-free rates after intraperitoneal chromic phosphate; stage I ovarian adenocarcinoma.
Piver MS; Lele SB; Bakshi S; Parthasarathy KL; Emrich LJ
Am J Clin Oncol; 1988 Oct; 11(5):515-9. PubMed ID: 3177251
[TBL] [Abstract][Full Text] [Related]
9. CA-125 levels after surgical exploration and radioactive chromic phosphate in ovarian cancer patients.
Makhija S; Spanos WJ; Day TG; Doering D
Gynecol Oncol; 1996 Oct; 63(1):85-8. PubMed ID: 8898174
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica.
Bolis G; Colombo N; Pecorelli S; Torri V; Marsoni S; Bonazzi C; Chiari S; Favalli G; Mangili G; Presti M
Ann Oncol; 1995 Nov; 6(9):887-93. PubMed ID: 8624291
[TBL] [Abstract][Full Text] [Related]
11. Distribution and tissue dose of intraperitoneally administered radioactive chromic phosphate (32P) in New Zealand white rabbits.
Leichner PK; Rosenshein NB; Leibel SA; Order SE
Radiology; 1980 Mar; 134(3):729-34. PubMed ID: 7355227
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal chromic phosphate P 32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging.
Soper JT; Wilkinson RH; Bandy LC; Clarke-Pearson DL; Creasman WT
Am J Obstet Gynecol; 1987 May; 156(5):1153-8. PubMed ID: 3578429
[TBL] [Abstract][Full Text] [Related]
13. Repetitive phosphorus-32 peritoneal instillations in a patient with malignant ascites.
Balink H; Sijmons EA; Zonnenberg BA; De Klerk JM
Clin Nucl Med; 2003 Jul; 28(7):545-7. PubMed ID: 12819405
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal chromic phosphate therapy after second-look laparotomy for ovarian cancer.
Varia M; Rosenman J; Venkatraman S; Askin F; Fowler W; Walton L; Halle J; Currie J
Cancer; 1988 Mar; 61(5):919-27. PubMed ID: 3338057
[TBL] [Abstract][Full Text] [Related]
15. Dose estimation to the infant from breast milk following intraperitoneal administration of chromic phosphate 32P for the treatment of early ovarian cancer.
Sharma SC; Osborne RP; Jose B; Carlson JA
Health Phys; 1984 Sep; 47(3):452-4. PubMed ID: 6500947
[No Abstract] [Full Text] [Related]
16. Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report.
Klaassen D; Shelley W; Starreveld A; Kirk M; Boyes D; Gerulath A; Levitt M; Fraser R; Carmichael J; Methot Y
J Clin Oncol; 1988 Aug; 6(8):1254-63. PubMed ID: 3045264
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging.
Soper JT; Berchuck A; Dodge R; Clarke-Pearson DL
Obstet Gynecol; 1992 Jun; 79(6):993-7. PubMed ID: 1579329
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant intraperitoneal chromic phosphate therapy in a woman with early ovarian carcinoma and pelvic infection with resulting catastrophic complications.
McGowan L
Clin Nucl Med; 1994 Aug; 19(8):696-8. PubMed ID: 7955749
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging.
Soper JT; Berchuck A; Clarke-Pearson DL
Cancer; 1991 Aug; 68(4):725-9. PubMed ID: 1855171
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal distribution imaging prior to chromic phosphate (P-32) therapy in ovarian cancer patients.
Tulchinsky M; Eggli DF
Clin Nucl Med; 1994 Jan; 19(1):43-8. PubMed ID: 8137583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
